What is Flow Pharma?
Flow Pharma is a biotechnology firm specializing in innovative immunotherapy solutions. The company leverages patented delivery systems and advanced biotechnology to develop treatments and preventative measures for cancer and viral diseases. Their product pipeline includes FLOVID-20, a vaccine targeting COVID-19, and FlowVax, designed to combat various cancers, including treatment-resistant breast cancer and HPV-induced cancers. Flow Pharma's commitment is to deliver curative interventions via inhalation and intramuscular delivery, notably excluding animal-sourced materials or live viruses, thereby aiming to revolutionize healthcare with its cutting-edge immunotherapy technologies.
How much funding has Flow Pharma raised?
Flow Pharma has raised a total of $384K across 2 funding rounds:
Debt
$150K
Debt
$234K
Debt (2020): $150K with participation from PPP
Debt (2021): $234K led by PPP
Key Investors in Flow Pharma
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Flow Pharma?
With its large-scale late-stage funding, Flow Pharma is strategically positioned to accelerate the development and commercialization of its immunotherapy pipeline. The recent major strategic investment signals strong confidence from backers in the company's potential to address significant unmet needs in oncology and virology. Future endeavors will likely focus on advancing clinical trials, expanding manufacturing capabilities, and securing regulatory approvals for its innovative treatments, particularly for COVID-19 and various cancer indications. This capital infusion is critical for Flow Pharma to solidify its market presence and achieve its goal of transforming healthcare.
See full Flow Pharma company page
